Chartwell Pharmaceuticals
Monique Weitz has extensive work experience in the pharmaceutical industry. Monique is currently working at Chartwell Pharmaceuticals as the Executive Vice President of Regulatory Affairs. Prior to that, they worked at Virtus Pharmaceuticals as the Vice President of Regulatory Affairs and Quality Assurance from June 2015 to September 2016. From August 2013 to June 2015, they served as the Head of Regulatory Affairs - U.S. at Cipla Ltd. Monique also held positions at Actavis formerly Abrika Pharmaceuticals, Abrika Pharmaceuticals, Elan Pharmaceuticals formerly Sano Corporation, Sano Corporation, and Envirodyne Inc. Overall, they have played key roles in regulatory affairs, project management, and quality assurance throughout their career.
Monique Weitz holds a Master of Business Administration (MBA) degree in Business, Management, Marketing, and Related Support Services from Florida Atlantic University. Monique also earned a Bachelor of Arts (BA) degree in Chemistry and a Bachelor of Science (BS) degree in Biology, General, both from Florida Atlantic University. In terms of certifications, Monique obtained a Regulatory Affairs Professionals Society (RAPS) certification in November 2020. Information about their other certifications, such as the American Society for Quality Certificate in Quality Engineering (CQE), the Master's Certificate in Project Management from The George Washington University, the Regulatory Affairs Professionals Society (RAPS) certification, the Project Management Professional (PMP) Certification, and the US Regulatory Affairs Certification (RAC), is not available.
This person is not in any offices
Chartwell Pharmaceuticals
CHARTING A COURSE TO WELLNESS Chartwell Pharmaceuticals is a US-based development, manufacturing and commercial organization located in Congers, New York. Our facility produces prescription pharmaceutical products with a commitment to superior quality, compliance, and customer service. Chartwell Pharmaceuticals has a long history as a preferred manufacturing partner for prescription solid dosage products in tablet, capsule, and powders forms. Recent expansion now adds capabilities for suspensions, enemas and liquids manufacturing - including Unit Dose cups. Our rooms are large, our ceilings are high, and facilities are pristine. Our exceptional hands-on leadership team and technical staff bring decades of pharmaceutical industry experience in manufacturing and analytical services for development, scale-up, transferring, changing, launching, and supplying products. Under our own Chartwell labels, our mission is to provide a consistent, timely and quality product supply to our pharmacy customers and their patients. Our current portfolio stands at over 250 Orange Book listed ANDAs and NDAs, with an aggressive asset development and acquisition program in place. Supported by Chartwell Labs, our Formulations and Analytical team, we are quickly continuing to broaden our line through commercial Chartwell-labeled branding. Chartwell Pharmaceuticals is proud to be manufacturing "Made in the USA" products.